Astrana Health, Inc. (ASTH) - Q2 2024 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Astrana Health, Inc. for the period ended June 30, 2024. Astrana is a physician-centric, technology-powered, risk-bearing healthcare management company operating primarily in California, Nevada, and Texas. The company manages care for approximately 1.0 million patients through 18 risk-bearing organizations. The reporting period reflects significant growth driven by strategic acquisitions and the expansion of its value-based care model.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in millions) |
|---|---|
| Total Revenue | $890.6 |
| Net Income (Astrana) | $34.0 |
| Operating Income | $60.2 |
| Adjusted EBITDA | $90.2 |
| Cash and Cash Equivalents | $325.3 |
| Total Debt | $446.1 |
| Working Capital | $260.5 |
| Diluted EPS | $0.71 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 30% ($205.2 million) compared to the six months ended June 30, 2023. This was primarily driven by a 35% increase in capitation revenue due to recent acquisitions (CFC, AHMS) and enrollees transitioning to full risk.
- Profitability: Net income attributable to Astrana increased by 29% to $34.0 million. Operating income rose 22% to $60.2 million.
- Expense Increases: Cost of services increased 28% and General and Administrative (G&A) expenses increased 65%, largely attributable to operational growth and integration of acquired entities.
- Interest Expense: Interest expense surged 134% to $16.2 million due to increased borrowings on the Amended Credit Facility to fund acquisitions and operations.
- Segment Performance: The Care Partners segment drove growth with a 33% revenue increase and 67% operating income increase. The Care Delivery segment returned to profitability with $1.6 million operating income compared to a loss in the prior year.
Guidance, Outlook, and Risks
2024 Guidance Update: Management updated its full-year 2024 guidance as follows:
- Total Revenue: $1,750 million – $1,850 million
- Net Income (Astrana): $54 million – $66 million
- Adjusted EBITDA: $165 million – $185 million
- Diluted EPS: $1.12 – $1.36
Recent Developments & Outlook:
- Acquisitions: The company announced a definitive agreement to acquire Collaborative Health Systems, LLC (CHS) for $37.5 million plus up to $21.5 million in earnouts, expected to close in Q4 2024.
- Partnerships: Formed a strategic partnership with Elation Health (technology platform) and Anthem Blue Cross (collaborative care clinic).
- Liquidity: The company maintains a $400 million revolving credit facility and a $300 million term loan. As of June 30, 2024, $146.7 million was drawn on the revolver.
Risks and Contingencies:
- Regulatory: Subject to complex Medicare and Medicaid regulations; potential for fines or exclusion from programs.
- Contingent Considerations: Significant liabilities exist for contingent consideration related to acquisitions (AAMG, CFC, ADSC, PCCCV), totaling approximately $38.2 million in fair value as of June 30, 2024.
- Interest Rate Risk: A significant portion of debt is floating-rate (SOFR), though partially hedged via an interest rate collar.
Investor Verification Checklist
- Acquisition Integration: Verify the financial performance and integration progress of CFC and AHMS, which drove the majority of Q2 revenue growth.
- Debt Servicing: Monitor the impact of rising interest rates on the $446 million debt load and the company's ability to maintain leverage ratios under the credit agreement.
- CHS Acquisition: Confirm the closing timeline and financing details for the $37.5 million CHS acquisition announced in July 2024.
- Capitation Trends: Assess the sustainability of the 35% capitation revenue growth and the transition of enrollees to full-risk models.
- Contingent Liabilities: Review the probability-weighted models used to value contingent consideration liabilities, as changes in fair value impact G&A expenses.